SCHEMBL18909497

SCHEMBL18909497

CC(C)(C)c1ccc(CC(C)(C)c2cc3ccccc3o2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.39
AGXT P21549 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAOB P27338 3/20 0.33
MAOA P21397 2/20 0.33
GLA P06280 1/20 0.33
CYP2A6 P11509 2/20 0.33
KDM4E B2RXH2 2/20 0.33
FLT3 P36888 1/20 0.33
MGLL Q99685 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP19A1 P11511 1/20 0.32
HTR1A P08908 1/20 0.32
HTR2B P41595 1/20 0.32
CA12 O43570 2/20 0.32
CA9 Q16790 2/20 0.32
CYP1A2 P05177 1/20 0.32
NT5E P21589 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL800706 0.79 KDM4E (0.44) LOXL2AGXTMEN1KMT2AMAOB
SCHEMBL10287250 0.76 LOXL2 (0.43) LOXL2AGXTMEN1KMT2AMAOB
SCHEMBL21275553 0.74 LOXL2 (0.42) LOXL2AGXTMEN1KMT2AMAOB
SCHEMBL6000886 0.74 CYP2A6 (0.42) LOXL2AGXTMEN1KMT2AMAOB
SCHEMBL23022772 0.71 KDM4E (0.33) LOXL2AGXTMEN1KMT2AMAOB
SCHEMBL27446124 0.70 MEN1 (0.36) LOXL2MEN1KMT2AMAOBMAOA
SCHEMBL1753926 0.69 MITF (0.33)
SCHEMBL19718547 0.69 HDAC1 (0.32) LOXL2MEN1KMT2ACYP2A6FLT3
SCHEMBL22888790 0.69 RAB9A (0.37) MEN1KMT2AMAOBMAOAKDM4E
SCHEMBL5776749 0.69 FLT3 (0.46) LOXL2AGXTMEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683277-B2 Triazole derivatives as P2Y14 receptor antagonists THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2020-06-16 US disclosed
US-9981901-B2 IRE-1α inhibitors FOSUN ORINOVE PHARMATECH, INC. (CN) 2018-05-29 US disclosed
US-20170152206-A1 IRE-1alpha INHIBITORS FOSUN ORINOVE PHARMATECH, INC. (CN) 2017-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152206-A1 IRE-1alpha INHIBITORS XBP1, DDIT3, ERN1 LOXL2 4340/4885AGXT 2761/4885MEN1 3492/4885
US-10683277-B2 Triazole derivatives as P2Y14 receptor antagonists GPR119, P2RY14, P2RY4 LOXL2 3859/4885AGXT 4254/4885MEN1 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.